---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Humanistic burden and health-related quality of life. Topics: Dermatology Life Quality Index overall and by body surface area: UPLIFT survey in North America, Europe, and Japan; Dermatology Life Quality Index with special-area involvement and limited body surface area: UPLIFT survey; Positive depression screen and quality of life impairment in survey respondents with psoriasis or psoriatic arthritis; Itch, pain, fatigue, Dermatology Life Quality Index, and EQ-VAS by severity: U.S. Corrona Psoriasis Registry, 1,529 patients on systemic therapy; 13 further topics. 17 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Dermatology Life Quality Index overall and by body surface area: UPLIFT survey in North America, Europe, and Japan

> “UPLIFT was a large, online, population-based survey conducted in North America, Europe, and Japan.”
> “Overall, in patients with PsO and/or PsA (n = 3614), mean DLQI score was 9.3, and 56% of patients experienced at least a moderate impact on QOL (DLQI score > 5).”
> “Among patients with PsO and/or PsA with limited BSA (≤ 3 palms; n = 2497), 56% had DLQI score > 5; 80% of patients with moderate BSA (4–10 palms) and 88% of patients with large BSA (> 10 palms) had DLQI total score > 5.”

Source: [Lebwohl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8547901/)

<a id="topic-2.2.1.8.1-2"></a>

### Dermatology Life Quality Index with special-area involvement and limited body surface area: UPLIFT survey

> “In patients with PsO involvement in at least one special area (n = 2776), the mean (SD) DLQI total score was 9.9 (8.5) and 57.9% reported DLQI total score > 5.”
> “In UPLIFT, 60% of PsO patients with limited BSA and involvement (BSA ≤ 3 palms) in at least one special area (n = 1927) reported their current disease as moderate or severe. Of these, 51% were receiving topical treatment or no treatment. In this group of patients, mean DLQI score was 9.4, and more than half of patients (56.4%) had a DLQI score > 5.”

Source: [Lebwohl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8547901/)

<a id="topic-2.2.1.8.1-3"></a>

### Positive depression screen and quality of life impairment in survey respondents with psoriasis or psoriatic arthritis

> “Approximately half of patients (52%) with PsO and/or PsA (n = 3806) screened positive for potential major depressive disorder, according to PHQ-2 guidelines (i.e., PHQ-2 score ≥ 3).”
> “Patients with DLQI total score > 5 and PsO in at least one special area who also had PHQ-2 score ≥ 3 had higher mean (SD) DLQI total scores [16.8 (6.7); n = 1203] compared with all patients with DLQI total score > 5 and PsO in at least one special area [15.5 (6.85); n = 1607, without positive depression screen].”

Source: [Lebwohl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8547901/)

<a id="topic-2.2.1.8.1-4"></a>

### Itch, pain, fatigue, Dermatology Life Quality Index, and EQ-VAS by severity: U.S. Corrona Psoriasis Registry, 1,529 patients on systemic therapy

> “The Corrona Psoriasis Registry is an independent, prospective observational cohort launched in April 2015 in collaboration with the National Psoriasis Foundation, with a target enrolment of 10 000 patients with psoriasis from 200 sites throughout the USA.”
> “1529 adult patients with psoriasis being treated with biological or non-biological systemic psoriasis treatment by 31 May 2016.”
> “As of 31 May 2016, 1529 patients were enrolled in the registry; the mean age was 50.6 years and 47% were female.”
> “BSA percentages were categorised as mild (0%–5%), moderate (>5%–10%), severe (>10%–15%) and very severe (>15%).”
> “Across BSA categories, mean fatigue scores ranged from 26.5 to 40.2, itching was 24.7 to 55.7 and pain was 15.2 to 41.7. Among IGA categories, mean fatigue scores ranged from 21.9 to 41.8, itching was 12.1 to 57.3 and pain was 7.4 to 44.3.”
> “Across BSA and IGA categories, mean DLQI scores ranged from 5.2 to 10.2 and 4.3 to 9.7, respectively. Mean EQ-VAS scores ranged from 62.9 (very severe) to 76.4 (mild) across BSA categories and 62.1 (severe) to 78.8 (clear/almost clear) across IGA categories, with higher scores indicating better health.”
> “Overall DLQI and EQ-VAS scores also worsened with disease severity (p<0.05 for each level of BSA and IGA) (table 2).”

Source: [Strober et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6500315/)

<a id="topic-2.2.1.8.1-5"></a>

### EQ-5D and Dermatology Life Quality Index differences by severity: U.S. survey of 694 patients

> “During a recent US survey, dermatologists provided information on overall disease severity, symptom severity and comorbidities.”
> “The study analysed 694 patients (55% male; mean age: 44 years); 48%, 46% and 6% had mild, moderate and severe psoriasis, respectively. Scaling was the most common symptom, which was experienced by 82% of patients, followed by itching (73%) and pain (32%). Increased psoriasis severity was associated with increased itching, pain and scaling, and with reduced QoL (decrease in EQ-5D scores: moderate vs. mild -0.04, severe vs. mild -0.18; increase in DLQI: moderate vs. mild 2.97, severe vs. mild 7.95).”

Source: [Korman et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27061102/)

<a id="topic-2.2.1.8.1-6"></a>

### EQ-5D health state utility values: meta-analysis of 59 studies

> “For meta-analysis, we identified 70 utility scores from 59 studies: 22 for plaque psoriasis, 26 for psoriasis as a general condition, and 22 for psoriatic arthritis.”
> “The mean (95% CIs; I2) of the EQ-5D utility scores for psoriasis as a general condition, plaque psoriasis, and psoriatic arthritis was 0.748 (0.718, 0.777; 98.8%), 0.755 (0.727, 0.783; 98.6%), and 0.585 (0.538, 0.632; 98.2%), respectively.”
> “For psoriasis as a general condition and plaque psoriasis, factors such as country, psoriasis area and severity index (PASI), dermatology life quality index (DLQI) and questionnaire version (EQ-5D-3L or EQ-5D-5L) all significantly influenced the utility scores.”

Source: [Yang et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/32716651/)

<a id="topic-2.2.1.8.1-7"></a>

### Emotional wellbeing, embarrassment, concealment, pain, and pruritus: National Psoriasis Foundation surveys, 2003 to 2011

> “The National Psoriasis Foundation (NPF) conducts semiannual surveys and collects information regarding comorbid conditions, medication use, treatment patterns, impact on quality of life, and disease burden.”
> “From 2003 to 2011, 5,604 patients completed the surveys. Psoriasis and psoriatic arthritis affected overall emotional wellbeing in 88% of patients, and they interfered with enjoyment of life in 82%. Most patients reported experiencing anger (89%), frustration (89%), helplessness (87%), embarrassment (87%), and self-consciousness (89%). Many patients also actively concealed physical manifestations of their diseases (83%), and experienced pain (83%) and pruritus (93%) regularly.”

Source: [Armstrong et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3532407/)

<a id="topic-2.2.1.8.1-8"></a>

### Problem in daily life by self-reported severity: survey of 5,452 respondents

> “The patients were asked to assess how much of a problem psoriasis has been in their daily life on a scale of 0–10 (0 = no problem and 10 = a very large problem).”
> “A total of 5452 patients reported a median of 5 (interquartile range 3–7)”
> “Among these respondents, patients with mild psoriasis reported a median of 3 (interquartile range 1–6), whereas patients with severe psoriasis reported a median of 7 (interquartile range 4–9).”

Source: [Armstrong et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3532407/)

<a id="topic-2.2.1.8.1-9"></a>

### Emotional wellbeing, quality of life, self-image, and stigma: U.S. online survey of 793 patients, 2020 to 2021

> “In brief, the study was a cross-sectional, quantitative online survey conducted in the USA between 12 November 2020 and 19 May 2021 and comprised a 5-min eligibility screener followed by a 25-min online questionnaire.”
> “This analysis included 793 US patients with psoriasis; 43% also had PsA.”
> “Psoriasis negatively affected emotional well-being and quality of life (QoL) in the majority of patients (87% and 91%, respectively).”
> “Patients stated that their skin symptoms made them feel unattractive (42%), less confident about themselves (37%), ashamed of their skin (35%), depressed (33%), or ashamed of their body (30%; Supplementary Material Fig. S5b).”
> “Many patients also noted that they had experienced stigma and discrimination, such as people not understanding the impact the disease had on the patient’s life (36%), being asked if they were contagious (36%), and being stared at in public (34%) (Supplementary Material Fig. S5a).”

Source: [Armstrong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634971/)

<a id="topic-2.2.1.8.1-10"></a>

### Negative comments from others in conversations about psoriasis

> “The patients reported that, on an average month, their psoriasis came up in conversations with others a mean of 5.8 times (SD±10). Among these conversations on psoriasis, 51% contained negative comments from others regarding the disease.”

Source: [Armstrong et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3532407/)

<a id="topic-2.2.1.8.1-11"></a>

### Anticipated negative stereotypes and perceived stigma by patient-reported severity: University of Pennsylvania dermatology clinics, 106 participants

> “Patients with psoriasis were recruited from dermatology clinics at the University of Pennsylvania.”
> “Patients (n = 106) were 48.11% female, 70.75% white, and had a mean age ± SD of 47.90 ± 16.19 years old.”
> “Linear regression analyses demonstrated that patient-reported severe psoriasis, compared to mild psoriasis, was associated with greater anticipation of negative stereotypes, social avoidance, and perceived stigma from others (P values < .05). Physician-measured body surface area and global assessment scores were not significantly associated with any outcome.”

Source: [Wan et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7963348/)

<a id="topic-2.2.1.8.1-12"></a>

### Anxiety disorders and anxiety symptoms: meta-analysis of 101 studies

> “A total of 101 eligible articles were identified. Meta-analysis revealed different prevalence rates depending on the type of anxiety disorder: 15% [95% confidence interval [CI] 9–21] for social anxiety disorder, 11% [9–14] for generalized anxiety disorder, and 9% [95% CI 8–10] for unspecified anxiety disorder.”
> “Meta-analysis also showed a high prevalence of anxiety symptoms (34% [95% CI 32–37]). Case-control studies showed a positive association between psoriasis and unspecified anxiety disorder (odds ratio 1.48 [1.18; 1.85]) and between psoriasis and anxiety symptoms (odds ratio 2.51 [2.02; 3.12]).”

Source: [Jalenques et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9558761/)

<a id="topic-2.2.1.8.1-13"></a>

### Incident depression, anxiety, and suicidality by severity: UK population-based cohort

> “A population-based cohort study using data collected as part of patient's electronic medical record from 1987 to 2002.”
> “Clinical diagnosis of depression, anxiety and suicidality were compared among 146,042 mild psoriasis, 3,956 severe psoriasis, and 766,950 control patients.”
> “The adjusted hazard ratios for receiving a diagnosis of depression, anxiety and suicidality in patients with psoriasis compared to controls, were 1.39 (95% CI 1.37, 1.41), 1.31 (95% CI 1.29, 1.34) and 1.44 (95% CI 1.32, 1.57), respectively. The adjusted relative risk of depression was higher in severe (HR 1.72, 95% CI 1.57, 1.88), compared to mild psoriasis (HR 1.38, 95% CI 1.35, 1.40).”
> “We estimate that in the UK, in excess of 10,400 diagnoses of depression, 7,100 diagnoses of anxiety, and 350 diagnoses of suicidality are attributable to psoriasis annually.”

Source: [Kurd et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928071/)

<a id="topic-2.2.1.8.1-14"></a>

### Sleep quality and sleep disturbance: meta-analysis of 15 studies

> “Fifteen studies including 1274 patients with psoriasis and 775 controls were analysed. A higher PSQI (weighted mean difference [WMD] = 3.397, P < 0.001, I2 = 84.2%) and a higher risk for SD (odds ratio [OR] = 6.640, P < 0.001, I2 = 67.5%) were observed in patients with psoriasis compared with controls. Subgroup analyses revealed a greater difference in PSQI score and/or risk for SD between patients with psoriasis and controls in subgroups of psoriatic arthritis, moderate-to-severe psoriasis, shorter psoriasis duration, and younger age.”

Source: [Guo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37956475/)

<a id="topic-2.2.1.8.1-15"></a>

### Avoidance of sexual activity because of psoriatic disease

> “In terms of relationships, although 32% of patients reported that their partner loved them just the way they were, 21% said that they avoided having sex because of their condition or could not stand the thought of someone touching or seeing their skin (Supplementary Material Fig. S5c).”

Source: [Armstrong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634971/)

<a id="topic-2.2.1.8.1-16"></a>

### Erectile dysfunction: meta-analysis of eight studies

> “Overall, 1829449 participants (the mean age ranged from 44 years to 56.3 years) were included from 8 studies (6 cross-sectional, 1 cohort, and 1 case-control study); 39490 of whom were patients with psoriasis, with the mean disease duration from 6 months to 19.9 years.”
> “Synthesis results from the included studies revealed that psoriasis was significantly associated with an increased risk of ED in psoriatic patients (OR = 1.62, 95%CI: 1.37-1.91, P < 0.001; heterogeneity: I2 = 62.6%, P = 0.009).”

Source: [Zhao et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30470802/)

<a id="topic-2.2.1.8.1-17"></a>

### Female sexual dysfunction: meta-analysis of eight studies

> “Eight studies (five case-control, three cross-sectional) were eligible for review, encompassing 563 women with psoriasis and 525 controls.”
> “Psoriasis was associated with greater odds of female sexual dysfunction (OR 2.67, 95% CI 1.93,3.69; p < 0.0001).”

Source: [Shah et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/36456639/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
